The latest price target for Qiagen (NYSE:QGEN) was reported by Jefferies on December 10, 2024. The analyst firm set a price target for $54.00 expecting QGEN to rise to within 12 months (a possible 19.84% upside). 9 analyst firms have reported ratings in the last year.

The latest analyst rating for Qiagen (NYSE:QGEN) was provided by Jefferies, and Qiagen their buy rating.

The last upgrade for Qiagen NV happened on June 27, 2024 when Wolfe Research raised their price target to $50. Wolfe Research previously had a peer perform for Qiagen NV.

The last downgrade for Qiagen NV happened on October 17, 2024 when HSBC changed their price target from N/A to N/A for Qiagen NV.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Qiagen, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Qiagen was filed on December 10, 2024 so you should expect the next rating to be made available sometime around December 10, 2025.

While ratings are subjective and will change, the latest Qiagen (QGEN) rating was a with a price target of $42.00 to $54.00. The current price Qiagen (QGEN) is trading at is $45.06, which is within the analyst’s predicted range.